Alexion wins EMA nods for not one but two drugs

Eric Palmer

Rare-disease specialist Pharmaceuticals won a double header from the EMA today when the agency recommended approval of two of its , including Kanuma, the enzyme replacement med it picked up in its $ 8.4 billion buyout of Synageva.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS